本报讯 （记者丁蓉）1月22日，第二届北大医疗产业集团有限公司（以下简称"北大医疗集团"）开放日 在北京、深圳两地同步举行。活动以"一切为了患者——走进今天的北大医疗"为主题，集中展示年度服 务成果与未来战略蓝图。 基于"健－医－康"闭环，2025年北大医疗集团收获了一张逆势增长的成绩单。北大医疗集团党委书记、 董事长朱友刚介绍，凭借"健－医－康"全周期服务的创新实践，2025年，北大医疗集团业绩实现稳健增 长，其中非医保收入增速达35%，门急诊人次突破320万人次，聚焦学科建设，三四级手术量同比增长 20%，门诊患者满意度、住院患者满意度双双创下历史最佳纪录。 打造"健－医－康"三大板块 作为中国平安保险（集团）股份有限公司（以下简称"中国平安"）"综合金融+医疗养老"战略的核心业 务成员，北大医疗集团携手北京大学医学部深化协同，通过"管理+学科+科研+品牌"四维赋能，共建公 立与社会办医协同发展典范。 "领军专家"是核心支柱，北大医疗集团以灵活的机制吸引30多位国家一级学会主委/副主委，60多位各 级学会主委/副主委领军的专业团队。 "价值医疗"强保障。北大医疗集团聚焦客户核心用药需求，覆盖超过350款独 ...

Core Viewpoint - The recent acquisition of a 9.75% stake in Daxin Pharmaceutical by Peking University Pharmaceutical is a strategic move to regain control over a previously divested asset, despite the company's ongoing financial struggles and the associated risks of the transaction [2][4][6]. Group 1: Acquisition Details - Peking University Pharmaceutical acquired the 9.75% stake in Daxin Pharmaceutical for 22 million yuan, with the transaction being completed swiftly on the same day as the auction [3][4]. - The total equity value of Daxin Pharmaceutical is approximately 233 million yuan, with a valuation increase of 28.52% [4]. - The stake was previously pledged as collateral for a debt of approximately 1.32 billion yuan owed by Southwest Synthesis to Peking University Medical Group [5]. Group 2: Financial Performance of Daxin Pharmaceutical - Daxin Pharmaceutical reported a revenue of approximately 269 million yuan in 2024, with a loss of 27.48 million yuan, and a revenue of about 212 million yuan with a net profit of 63,600 yuan in the first eight months of 2025 [6]. - The company's net assets have decreased to approximately 181 million yuan, reflecting a significant decline from 271 million yuan in 2015 [6]. Group 3: Ongoing Legal and Operational Challenges - Peking University Pharmaceutical is involved in an arbitration case with Chongqing Synthesis regarding an asset transfer agreement, which has resulted in a ruling that may lead to increased operational costs due to personnel management issues [7][8]. - The company faces a potential revenue loss of approximately 600 million yuan and a net profit decrease of about 40 million yuan due to the termination of a long-term service contract with Peking University International Hospital [9]. - In the third quarter of 2025, Peking University Pharmaceutical experienced a 47.95% year-on-year decline in revenue, amounting to approximately 274 million yuan [9].

Core Insights - China Ping An Insurance (Group) Co., Ltd. reported significant advancements in its healthcare and elderly care strategy, with nearly 70% of new life insurance business value attributed to clients enjoying healthcare and elderly care ecosystem services [1] - The company achieved health insurance premium income of approximately 87 billion yuan, with medical insurance premium income exceeding 41 billion yuan, reflecting a year-on-year growth of 3.3% [1] - As of June 30, 2025, clients with healthcare and elderly care ecosystem service rights had an average of 3.37 contracts and an average AUM of approximately 61,400 yuan, which are 1.5 times and 4.1 times higher than those without such rights, respectively [1] Healthcare and Elderly Care Strategy - The company is enhancing its flagship internet medical platform and self-operated medical institutions, aiming to provide comprehensive services across various channels including online, in-store, at home, and at enterprises [1] - Ping An Good Doctor reported a revenue of 2.502 billion yuan and a net profit of 134 million yuan in the first half of the year [1] - The AI medical product matrix launched by Ping An Good Doctor covers over 10,000 diseases with a diagnostic accuracy rate of 93% [1] Collaboration and Network - The Beijing University Medical Group generated over 2.66 billion yuan in revenue in the first half of the year, with the Beijing University International Hospital contributing nearly 1.26 billion yuan [1] - The company has established a network of approximately 50,000 internal and external doctors, achieving 100% cooperation coverage with top 100 hospitals and tier-three hospitals in China [1]